Discovery of Novel <i>N</i>-β-<scp>d</scp>-Xylosylindole Derivatives as Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Management of Hyperglycemia in Diabetes
作者:Chun-Hsu Yao、Jen-Shin Song、Chiung-Tong Chen、Teng-Kuang Yeh、Ming-Shiu Hung、Chih-Chun Chang、Yu-Wei Liu、Mao-Chia Yuan、Chieh-Jui Hsieh、Chung-Yu Huang、Min-Hsien Wang、Ching-Hui Chiu、Tsung-Chih Hsieh、Szu-Huei Wu、Wen-Chi Hsiao、Kuang-Feng Chu、Chi-Hui Tsai、Yu-Sheng Chao、Jinq-Chyi Lee
DOI:10.1021/jm101072y
日期:2011.1.13
activity against sodium-dependent glucose cotransporter 2 (SGLT2) in a cell-based assay. Of these, the 4-chloro-3-(4-cyclopropylbenzyl)-1-(β-d-xylopyranosyl)-1H-indole 19m was found to be the most potent inhibitor, with an EC50 value similar to that of the natural SGLT2 inhibitor phlorizin. Further studies in Sprague−Dawley (SD) rats indicated that 19m significantly increased urine glucose excretion in
合成了一系列新的N-连接的β- d-木糖苷,并在基于细胞的测定中评估了其对钠依赖性葡萄糖共转运蛋白2(SGLT2)的抑制活性。其中,4-氯-3-(4-环丙基苄基)-1-(β- d-吡喃并吡喃糖基)-1H-吲哚19m被认为是最有效的抑制剂,其EC 50值与天然SGLT2抑制剂phlorizin。对Sprague-Dawley(SD)大鼠的进一步研究表明,口服给药19m可以剂量依赖性显着增加尿液葡萄糖的排泄。的降糖效果19米在链脲佐菌素(STZ)诱导的糖尿病SD大鼠中也观察到了这种现象。此处描述的这些结果为进一步研究N-糖苷SGLT2抑制剂提供了良好的起点。